Press for SynapDx
SynapDx Corporation announced today that is has obtained an exclusive world-wide license to technology from Children's Hospital Boston to accelerate the Company's development of blood-based tests to enable the early detection of Autism Spectrum Disorders. The discoveries were developed through collaboration by leading Children's researchers, Dr. Louis Kunkel and Dr. Isaac Kohane. In 2010, SynapDx also obtained exclusive world-wide rights to blood-based autism detection technologies from George Washington University, based on the work of Dr. Valerie Hu.
SynapDx Corporation announced today that Thomas Mac Mahon has joined its board of directors. Thomas Mac Mahon was President and Chief Executive Officer and a member of the Executive and Management Committees of Laboratory Corporation of America (LabCorp) from January 1997 until his retirement at the end of 2006.